Hands-on with Huawei Honor 8 dual-camera phone with 5.2" full HD display, 8-core Kirin 950 SoC, 4GB RAM, now available for pre-order in the US starting at $399
Huawei's second US-bound “Honor” phone brings another budget flagship option to the table. — Huawei might not be well known in the US …
Context & Ripple Effects
Huawei's US ladder is climbing rung by rung: after the $199.99 Honor 5X opened the budget door in January, the Honor 8 more than doubles the price to $399 while carrying the same Kirin 950 SoC that debuted in the Mate 8 flagship — a deliberate trickle-down of last year's top silicon into the midrange.
The dual-lens camera is the differentiator this time, not just specs-per-dollar, and it sets the template for what follows: the Honor 8 Pro and the Honor 9's European debut both keep the multi-camera formula, though the Honor 9 ships with no US pricing or release date.
First-order effects
- US buyers get a $399 phone with flagship-grade internals — the Mate 8's Kirin 950 and 4GB RAM — directly undercutting incumbent flagships on price.
- Huawei extends its US retail beachhead beyond the $200 tier, testing whether American consumers will pay midrange money for an unfamiliar brand.
Second-order effects
- Rivals selling near-$400 phones now face a spec sheet built from last year's flagship parts, pressuring them to cut prices or accelerate their own component trickle-downs.
- The Honor 9's Europe-only launch with no US date signals the US channel remains the fragile link in Huawei's expansion, even as the product line matures elsewhere.
Third-order effects
- If the pattern holds, dual-lens cameras become table stakes across all price tiers rather than a flagship exclusive, resetting buyer expectations for what $399 buys.
- Huawei's sub-brand structure — Honor for volume markets, Mate/P-series for flagships — points toward Chinese vendors competing on component reuse and cadence rather than single hero devices.
The trend: Chinese smartphone makers are scaling sub-brands upmarket on reused flagship silicon, with the US market treated as an opportunistic test bed behind China and Europe.